The APH1B Knockout A-549 Polyclonal Cells product consists of a heterogeneous population of A-549 human lung adenocarcinoma epithelial cells that have undergone CRISPR/Cas9-mediated gene disruption at the APH1B locus. This polyclonal knockout pool provides a physiologically relevant loss-of-function model for interrogating gamma-secretase complex biology without the clonal selection bias inherent in single-cell-derived lines. The targeted disruption of APH1B abrogates expression of a core subunit of the gamma-secretase protease, enabling researchers to dissect the functional consequences of impaired intramembrane proteolysis in a well-characterized epithelial cancer background.
The parental A-549 cell line was originally derived from the lung adenocarcinoma tissue of a 58-year-old male and has since become a widely adopted model for respiratory epithelium and non-small cell lung cancer. These adherent cells retain key features of pulmonary epithelial differentiation and are commonly employed to study oncogenic signaling, drug response, and cellular mechanisms underlying tumor progression. Their robust growth characteristics and genetic tractability make them particularly suitable for CRISPR-based genome editing and subsequent functional genomics studies.
APH1B encodes a presenilin-stabilizing subunit of the gamma-secretase complex, which is responsible for the intramembrane cleavage of type I transmembrane proteins including Notch receptors and amyloid precursor protein (APP). Within the complex, APH1B interacts directly with presenilin-1 (PSEN1), presenilin-2 (PSEN2), nicastrin (NCSTN), presenilin enhancer-2 (PSENEN), and its homolog APH1A. Disruption of APH1B impairs the catalytic activity of gamma-secretase, thereby attenuating the release of Notch intracellular domain (NICD) and the subsequent transcriptional activation of target genes such as HES1 and HEY1. Similarly, APH1B loss reduces production of APP intracellular domain and APP C-terminal fragments, linking this model to both Notch-dependent developmental programs and Alzheimer’s disease-relevant amyloidogenic processing.
In the context of A-549 lung adenocarcinoma cells, the APH1B knockout model offers a unique platform to explore how gamma-secretase-dependent signaling contributes to cancer cell behavior. Notch pathway activity has been implicated in lung tumor initiation, maintenance, and chemoresistance, while APP processing pathways may intersect with oncogenic signaling networks. The polyclonal knockout population permits the study of heterogeneous cellular responses to APH1B loss, including alterations in proliferation, apoptosis, migration, and invasion, and provides a more representative model of tumor cell diversity than clonal isolates.
This knockout cell product is well-suited for a broad range of experimental workflows. Researchers can perform western blotting to monitor changes in NICD levels or APP cleavage fragments, quantitative RT-PCR to measure HES1 and HEY1 transcript abundance, and RNA-sequencing for global transcriptome profiling under gamma-secretase compromise. Co-immunoprecipitation assays enable assessment of residual gamma-secretase complex assembly, while flow cytometry can quantify cell surface Notch receptor expression. Functional assays including apoptosis detection and transwell migration/invasion studies further extend the utility of these cells in both cancer biology and neurodegeneration research. For further details or to discuss custom applications, please contact Ascent Research.
